Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 326 | 47% |
| 2020 | 8 | 387 | 49% |
| 2021 | 11 | 448 |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 47% of the cases CMS names in Pennsylvania; 21 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 25 | 1,148+12%/yr | +12%/yr | 0.6 | 0% | 1,980 in 2030+9.5%/yr |
| Massachusetts | 13 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 30 | 767+7.4%/yr | +7.4%/yr | 0.61.5× | 0% | 1,030 in 2030+5%/yr |
| DBS & VNS |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
| 2024 |
| 803 |
| 58% |
| 2025 est. | ≈ 970 | – |
| 2026 est. | ≈ 1,060 | – |
| 51% |
| 2022 | 16 | 547 | 53% |
| 2023 | 20 | 681 | 56% |
| 2024 | 29 | 803 | 58% |
| 2025 from claims | – | 969 784–1,138 | 59% |
| 2026 forecast | – | 1,065 834–1,337 | 59% |
| 2027 forecast | – | 1,155 856–1,526 | 59% |
| 2028 forecast | – | 1,251 886–1,727 | 60% |
| 2029 forecast | – | 1,356 922–1,945 | 60% |
| 2030 forecast | – | 1,470 963–2,181 | 61% |
In 2025, 98% inpatient hospital, 2% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~1,100 | ~1,000 | ~17 |
| 2027 · ~1,200 | ~1,100 | ~17 |
| 2028 · ~1,300 | ~1,200 | ~18 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 456+8%/yr |
| +8%/yr |
| 0.5 |
| 0% |
| 820 in 2030+10%/yr |
| New Jersey | 13 | 399+11%/yr | +11%/yr | 0.4 | 0% | 600 in 2030+7.1%/yr |
| Connecticut | 6 | 214+31%/yr | +31%/yr | 0.6 | 0% | 330 in 2030+7.6%/yr |
| 4 |
| 485−4.3%/yr |
| −4.3%/yr |
| 0.31.5× |
| 0% |
| 620 in 2030+4.1%/yr |
| CSF shunts | 2 | 238−9.5%/yr | −9.5%/yr | 0.20.8× | 0% | 280 in 2030+2.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Stryker leads with 30% of company spending on these surgeons in 2025, +20 pts on 2024.
In 2025, 11 companies reported engagement with Pennsylvania’s surgeons worth $574K in consulting, speaking, meals and travel tied to these products, about $20K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.